Int. J. Mol. Sci. 2012, 13(11), 14470-14491; doi:10.3390/ijms131114470

Experimental and Therapeutic Opportunities for Stem Cells in Multiple Sclerosis

1,2email and 3,* email
Received: 5 September 2012; in revised form: 22 October 2012 / Accepted: 5 November 2012 / Published: 8 November 2012
(This article belongs to the Special Issue Recent Advances in the Research of Multiple Sclerosis)
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract: Multiple Sclerosis (MS) is an inflammatory demyelinating neurodegenerative disorder of the brain and spinal cord that causes significant disability in young adults. Although the precise aetiopathogenesis of MS remains unresolved, its pathological hallmarks include inflammation, demyelination, axonal injury (acute and chronic), astrogliosis and variable remyelination. Despite major recent advances in therapeutics for the early stage of the disease there are currently no disease modifying treatments for the progressive stage of disease, whose pathological substrate is axonal degeneration. This represents the great and unmet clinical need in MS. Against this background, human stem cells offer promise both to improve understanding of disease mechanism(s) through in-vitro modeling as well as potentially direct use to supplement and promote remyelination, an endogenous reparative process where entire myelin sheaths are restored to demyelinated axons. Conceptually, stem cells can act directly to myelinate axons or indirectly through different mechanisms to promote endogenous repair; importantly these two mechanisms of action are not mutually exclusive. We propose that discovery of novel methods to invoke or enhance remyelination in MS may be the most effective therapeutic strategy to limit axonal damage and instigate restoration of structure and function in this debilitating condition. Human stem cell derived neurons and glia, including patient specific cells derived through reprogramming, provide an unprecedented experimental system to model MS “in a dish” as well as enable high-throughput drug discovery. Finally, we speculate upon the potential role for stem cell based therapies in MS.
Keywords: multiple sclerosis (MS); embryonic stem cells (ESCs); pluripotent stem cells (PSCs); induced pluripotent stem cells (iPSCs); neurodegenerative disease
PDF Full-text Download PDF Full-Text [376 KB, uploaded 19 June 2014 04:31 CEST]

Export to BibTeX |

MDPI and ACS Style

Patani, R.; Chandran, S. Experimental and Therapeutic Opportunities for Stem Cells in Multiple Sclerosis. Int. J. Mol. Sci. 2012, 13, 14470-14491.

AMA Style

Patani R, Chandran S. Experimental and Therapeutic Opportunities for Stem Cells in Multiple Sclerosis. International Journal of Molecular Sciences. 2012; 13(11):14470-14491.

Chicago/Turabian Style

Patani, Rickie; Chandran, Siddharthan. 2012. "Experimental and Therapeutic Opportunities for Stem Cells in Multiple Sclerosis." Int. J. Mol. Sci. 13, no. 11: 14470-14491.

Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert